
Rivaroxaban Tablets
RIVAROX 10
रिवारोक्स १०
3 Blisters of 10 Tablets
1st National Brand
Rivaroxaban Tablets
RIVAROX 15
रिवारोक्स १५
3 Blisters of 10 Tablets
Rivaroxaban Tablets
RIVAROX 20
रिवारोक्स २०
3 Blisters of 10 Tablets

DABICLOT

Dabigatran Etexilate 110/ 150 mg Capsule

CLINICAL PHARMACOLOGY

Pharmaco-therapeutic Group: Antithrombotic agents, Direct Thrombin Inhibitors.

Mechanism of Action: Dabigatran is a potent, competitive, reversible direct thrombin inhibitor and is the main active principle in plasma. Since thrombin (serine protease) enables the conversion of fibrinogen into fibrin during the coagulation cascade, its inhibition prevents the development of thrombus. Dabigatran inhibits free thrombin, fibrin-bound thrombin and thrombin-induced platelet aggregation.

DRUG-DRUG INTERACTIONS:

- Amiodarone, Dronedarone, medicines used to treat irregular heartbeats
- Verapamil, a calcium channel blocker used to treat high blood pressure and angina
- Clarithromycin or rifampicin, medicines used to treat infections
- Selective serotonin re-uptake inhibitors (SSRI), selective serotonin norepinephrine re-uptake inhibitors (SNRI), medicines used to treat mood disorders.

INDICATIONS:

- Reduction of Risk of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation
- Treatment of Deep Venous Thrombosis and Pulmonary Embolism and its recurrence
- Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism Following Hip Replacement Surgery

SPECIAL POPULATIONS:

Patients at risk of bleeding: Dose adjustment should be decided at the discretion of the physician, following assessment of the potential benefit and risk to an individual patient.For patients with gastritis, esophagitis, or gastro esophageal reflux, a dose reduction may be considered due to the elevated risk of major gastro-intestinal bleeding.

Renal impairment: Treatment with DABICLOT in patients with severe renal impairment is contraindicated.No dose adjustment is necessary in patients with mild renal impairment. For patients with moderate renal impairment the recommended dose of DABICLOT is also 300 mg taken as one 150 mg capsule twice daily.

Pediatrics population: For the indication DVT/PE, the safety and efficacy of DABICLOT in children from birth to less than 18 years of age have not yet been established.

Method of Administration: DABICLOT is for oral use. The capsules can be taken with or without food. DABICLOT should be swallowed as a whole with a glass of water, to facilitate delivery to the stomach.

SPECIAL WARNNINGS AND PRECAUTIONS:

Hemorrhagic risk: DABICLOT should be used with caution in conditions with an increased risk of bleeding or with concomitant use of medicinal products affecting hemostasis by inhibition of platelet aggregation. Bleeding can occur at any site during therapy with DABICLOT. Risk factors comprise co-medication with platelet aggregation inhibitors such as Clopidogrel and acetylsalicylic acid (ASA) or non-steroidal
anti-inflammatory drugs (NSAID).

Pregnancy: Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women.
Breast-feeding: There are no clinical data of the effect of DABICLOT on infants during breast-feeding.

CONTRAINDICATIONS:

- Hypersensitivity to the active substance or to any of the excipients

For Further Details:

QbD Pharmaceuticals Pvt. Ltd.

Market Planning Department

Email: mpd@qbdpharmaceuticals.com

Website: www.qbdpharmaceuticals.com

Introducing

An Effective Anticoagulant With No Monitoring Required....

Reduces the risk of Stroke in Non-Valvular Atrial Fibrilation[1]

DABICLOT

Dabigatran Etexilate 110/ 150 mg Capsule

Superior to **Warfarin**
at reducing the risk of
Stroke[1]

Requires
No Dietary Restrictions[1]

Shows better efficacy than **Warfarin** in
Renal Impairment and **Elderly Patients**[2]

1. New England Journal of Medicine (RE-LY Trial), 2009

2. Thrombosis and Haemostasis, 2017

DABICLOT

Dabigatran Etexilate 110/ 150 mg Capsule

Significantly reduces the 2 most devasting events for your patient[3]

Intracranial Hemorrhage

59%

risk reduction vs Warfarin[3]

35%

risk reduction vs Warfarin[3]

Ischemic Stroke

Breaks Down The Hardest Clot

3. Lancet, 2014

DABICLOT

Dabigatran Etexilate 110/ 150 mg Capsule

Requires

No Regular

Blood Test[4]

92%

RRR of

Recurrent VTE[5]

Breaks Down The Hardest Clot

4. Drug Safety, 2011

5. New England Journal of Medicine (RE-SONATE Trial), 2013

Lower HbA1C[2]

Lower the risk of CV Death[1]

Without Hypoglycemia[2]

Additional Benefits

Weight Loss[4]

BP Reduction[5]

References:

1. Circulation. (2016)
2. New England Journal of Medicine (2015)
3. ESC Guidelines (2019)
4. ADA Guidelines (2020)
5. European Journal of Clinical Pharmacology (2016)

QbD Pharmaceuticals Pvt. Ltd.
Market Planning Department
E-mail: qbd.mpd@gmail.com, www.qbdpharmaceuticals.com

2 OUT OF 3 DEATHS IN DIABETES, ARE DUE TO CVD[1]

Introducing

The first Type 2 Diabetes pill proven to go beyond lowering HbA1C to **reduce the risk of CV death…..**

GLUCOEMP

Empagliflozin 10/ 25 mg Tablet

Only oral anti-hyperglycemic agent proven to show significant reductions in

Major Adverse Cardiovascular Events (MACE)[3]

↓38% Cardiovascular Death[2]



↓35% Hospitalization for Heart Failure[2]



↓32% Mortality[2]



Also **14%** reduction in **Cardiovascular Events**[2]

Life can be sweeter with less sugar

ATOMOX

Atomoxetine HCL10/ 25/ 40 mg Capsules



Once Daily

Treatment for Attention Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder (ADHD)

Is neuro - developmental disorder, which has significant problems in executive functions.

Inattention, hyperactivity/ impulsiveness are the major problems resulting in significant impairment on academic performance vocational success, social-emotional development with profound impact on individuals, families and societies.

10% prevalence rate of ADHD in Nepal which is even higher than global prevalence (i.e. 5.29% and 7.2%).

- First FDA Approved Non-stimulant[1]
- Drug of Choice in Adolescents with ADHD[2]
- Provide Longer Duration of Action[3]
- Effective and Well Tolerated both in Younger and Older Children[4]
- Preferred Therapy Over other Stimulants[5]

Reference: 1. Indian Pediatrics; Vol.43. | 2. CNS Drugs 2005; 19(8). | 3. Am J Psychiatry 159:11, Nov.2002. 4. Child and Adolescent Psychiatry and Mental Health 2008, 2:25. | 5. Pharmacotherapy 2005; 25(11).

QbD

INTRODUCES

Nepal 's Ever First ATOMOXETINE Capsules

ATOMOX

Atomoxetine HCL10/ 25/ 40 mg Capsules

ATTENTION DEFICIT HYPERACTIVITY DISORDER

A Pioneer Product From

QbD Pharmaceuticals Pvt.Ltd
Market Planning Department
Email: mpd@qbdpharmaceuticals.com

1st National Brand

A Smart Drug

MODAF

Modafinil 100/ 200 mg Tablets

NARCOLEPSY

- **C**ataplexy
- **H**allucinations (Hypnagogic and/or Hypnopompic)
- **E**xcessive Daytime Sleepiness
- **S**leep Paralysis
- **S**leep Disruption

QbD Pharmaceuticals

VENLA-ER

Venlafaxine 37.5 / 75/ 150 mg
Extended Release Capsules

SCHIZOPRA

Aripiprazole 5/ 10/ 15 mg Tablets

AMILINE

Amitriptyline 10/ 25 mg Tablets

ESCITAL

Escitalopram 5/ 10 mg Tablets

For Further:

QbD Pharmaceuticals Pvt.Ltd
Market Planning Department
Email: mpd@qbdpharmaceuticals.com

VENLA-ER

Venlafaxine 37.5 / 75/ 150 mg Extended Release Capsules

With an Unique Dual Mechanism of Neurological Actions

Therapeutic Indications

- Major Depressive Episodes.
- Prevention of Recurrence of Major Depressive Episodes.
- Generalized Anxiety Disorder.
- Social Anxiety Disorder.
- Panic Disorder, With or Without Agoraphobia.

Dose

Recommended Dose: 37.5 mg/day Duration: 7 days.

- Dosage should then be increased to 75 mg/day.
- Maximum Dose: 225 mg/day.
- Dosage increases can be made at intervals of 2 weeks or more but not less than 4 days.

Why Venla-ER?

- Venla-ER is clinically superior and effective other than SSRIs and TCAs.
- It is safe, tolerable and effective for the treatment of severe depression.
- Its combined inhibition accounts for greater efficacy and rapid onset of action.
- It is better than fluoxetine in terms of improving symptoms and adverse events.
- It is superior compared with duloxetine.